Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

July 31, 2029

Study Completion Date

July 31, 2029

Conditions

AngiosarcomaAngiosarcoma, Adult

Interventions

BIOLOGICAL

Vusolimogene Oderparepvec (VO)

Given intratumorally

DRUG

Pembrolizumab

Given IV

Trial Locations (1)

University of California, San Francisco, San Francisco

All Listed Sponsors

collaborator

Replimune Inc.

INDUSTRY

lead

Varun Monga, MBBS

OTHER